Verla-Pharm modernizes regulatory compliance with eQMS solutions by DHC Business Solutions

The Verla-Pharm Arzneimittel GmbH & Co. KG relies on the industry and solution competence of DHC Business Solutions for modernization and digitalization of regulatory quality processes.

Verla-Pharm Arzneimittel GmbH & Co. KG – short: Verla – is an independent and traditional medium-sized company based in Tutzing on Lake Starnberg. Verla is market leader in the magnesium sector and is known for its minerals expertise. Fields of application are the treatment of magnesium and zinc deficiency, bone loss and gynecological complaints. Selected herbal medicines, natural substances and high-quality dietary supplements round off the product range. 

Tradition and innovation are not contradictory at Verla. It is therefore not surprising that the continuous modernization of the entire IT landscape at Verla is of high strategic relevance. While IoT solutions are already in place today, the digital connectivity of quality processes, which are highly sensitive to regulatory requirements, must also be guaranteed. The tools and solutions used to date are reaching their limits in terms of transparency and efficiency and with regard to meeting complex regulatory compliance requirements. Verla, therefore, has decided to replace the existing custom software solution with standard software from DHC Business Solutions. The changeover will take place in the area of so-called controlled processes (deviations, complaints and management of changes) and for controlled documents in SOP and training management.

Christian Paunert, Head of CGS Management at Verla, describes the associated goals as follows: “We are striving for the standardization and further automation of processes. We also want to intelligently utilize the potential of data diversity around the individual production batch. To do this, we need close integration of the DHC VISION eQMS with the ERP and MES systems used”. Verla has high expectations with regard to the new eQMS solution: “Previous paper-based workflows, for example in document control, are inefficient and error-prone; this should now change”. Christian Paunert: “We are rethinking our quality systems and processes and are thus creating a standardized, regulatory-compliant and digital foundation for our sustainable growth”. 

The decision for the eQMS from DHC Business Solutions was made during a selection process. In particular, the functional scope of the eQMS standard solution, its expandability, for example in the direction of quality analytics, as well as the geographical proximity to the provider with short decision-making paths in the project and to downstream support were convincing. But the expertise in validation was also a decisive factor: “What DHC Business Solutions offers here is quite convincing, even unique,” emphasizes Christian Paunert. “We get not only the software, but also the templates for a consistent validation documentation, which of course, has to be checked, extended if necessary and finally released by us. DHC will provide us with competent advice on validation; the consultants are familiar with the regulated environment; they know what they are talking about. 

Dr. Wolfgang Kraemer, Managing Director of DHC Business Solutions, adds: “Our unique selling point in the provider market for eQMS solutions is our affinity with SMEs in the life science industry. DHC Business Solutions can service medium-sized companies competently and on an equal footing. SMEs are more willing to orient themselves to best practice processes in their industry. This provides “time to market” advantages that would not be possible in larger corporate structures”. 

The partnership between Verla and DHC Business Solutions is therefore long-term, both project partners emphasize.


About Verla:

Verla-Pharm, one of the leading medium-sized companies in the German pharmaceutical market. For almost 70 years, Verla stands for competence in mineral therapy. Over the years, the company has grown and is a pioneer in Germany for modern mineral and vital substance therapy for the well-being of patients. 

Further information about Verla is available at